Oxford Nanopore Technologies PLC
Company Profile
Business description
Oxford Nanopore Technologies PLC makes a novel generation of DNA/RNA sequencing technology that provides rich data and is fast, accessible, and easy to use. The company is predominantly involved in researching, developing, manufacturing, and commercializing a nanopore-based sequencing platform that allows the real-time analysis of deoxyribonucleic acid (DNA) or ribonucleic acid (RNA). This enables its customers to perform scientific/biomedical research in a range of areas, including human genetics, cancer research, outbreak surveillance, environmental analysis, pathogens/antimicrobial resistance, microbiome analysis, and crop science. The company's reportable segments are; Life Science Research Tools which generates key revenue, and COVID Testing.
Contact
Edmund Halley Road
Gosling Building, Oxford Science Park
OxfordOxfordshireOX4 4DQ
GBRT: +44 8450347900
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
1,316
Stocks News & Analysis
stocks
This ASX supermarkets business is now underperforming its largest competitor
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,903.30 | 31.20 | 0.35% |
| CAC 40 | 8,062.31 | 86.19 | 1.08% |
| DAX 40 | 24,401.70 | 410.43 | 1.71% |
| Dow JONES (US) | 49,200.41 | 258.51 | 0.53% |
| FTSE 100 | 10,219.11 | 144.82 | -1.40% |
| HKSE | 25,898.61 | 197.27 | -0.76% |
| NASDAQ | 25,318.51 | 250.71 | 1.00% |
| Nikkei 225 | 59,513.12 | 228.20 | 0.38% |
| NZX 50 Index | 13,035.70 | 61.98 | -0.47% |
| S&P 500 | 7,258.75 | 58.00 | 0.81% |
| S&P/ASX 200 | 8,680.50 | 38.80 | 0.45% |
| SSE Composite Index | 4,112.16 | 4.65 | 0.11% |